Modality
Degrader
MOA
IL-13i
Target
VEGF
Pathway
NF-κB
CKD
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
Mar 2021
→ Oct 2029
Phase 1Current
NCT03589849
2,298 pts·CKD
2025-05→2029-10·Active
NCT05045462
1,997 pts·CKD
2021-03→2026-03·Not yet recruiting
4,295 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-03-202w agoPh2 Data· CKD
2026-07-194mo awayEnrollment Complete· CKD
2029-10-153.5y awayPh2 Data· CKD
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Not yet…
P1/2
Active
Catalysts
Ph2 Data
2026-03-20 · 2w ago
CKD
Enrollment Complete
2026-07-19 · 4mo away
CKD
Ph2 Data
2029-10-15 · 3.5y away
CKD
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03589849 | Phase 1/2 | CKD | Active | 2298 | MRD |
| NCT05045462 | Phase 1/2 | CKD | Not yet recr... | 1997 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |